AUTOIMMUNITY part 72

 

Immune 4

ANTI-B-LYMPHOCYTE THERAPY

Rituximab is a cytotoxic chimeric human mouse monoclonal antibody with a high affinity for CD20, a pan-B-cell surface antigen. It was developed originally for the treatment of B-cell lymphomas. The killing of B cells by rituximab is thought to depend on both of the specific  recognition of B cells by this monoclonal antibody and natural killer (NK) cell-mediated antibody -dependent cellular cytotoxicity (ADCC) of those cells. There is considerable evidence that the interaction of B-cell-bound monoclonal antibodies  with NK cell CD16 (FcγRIIIA) is a critical event leading to ADCC following treatment with rituximab. Rituximab appears to have activity in a variety of autoimmune  diseases associated with autoantibody production including RA, SLE, polymyositis/dermatomyositis, sjogren’s syndrome, and cryoglobulinemic vasculitis.

Advertisements

About azaleaazelia

A nice person... :)
This entry was posted in Tak Berkategori. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s